Recent News
Powered by Alpha Vantage
No recent news found.
AI Tools
Key Metrics
Trend: Range-Bound
As of 2025-09-10 (Snapshot)
Protalix BioTherapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of recombinant therapeutic proteins based on its proprietary ProCellEx plant cell-based protein expression system in Israel, Brazil, the rest of Latin America and internationally. The company is headquartered in Karmiel, Israel.
52W High
$3.10
52W Low
$0.98
MA Status:
50D: Above
200D: Below
Beta (~1 neutral, <0.9 lower risk)
-0.23
Valuation
Attractive
As of 2025-06-30 (Overview)
Trailing P/E (<15 better)
17.11
Forward P/E (<15 better)
2.83
EV/EBITDA (<8 favorable)
9.12
EV/Revenue (<3 favorable)
1.53
P/S (TTM) (<3 favorable)
1.98
P/B (<3 favorable)
2.46
Ownership
Retail‑heavySource: Overview
Insiders (1–5% typical)
10.54%
Institutions (25–75% balanced)
15.14%
Shares Outstanding
79,732,000
Float
60,755,000
Dividend Yield (2–6% sweet spot)
N/A
Ex‑Dividend Date
N/A
Income & Growth
Profitability: Weak
As of 2025-06-30 (Overview)
Revenue (TTM)
61,948,000
Gross Profit (TTM)
35,637,000
EPS (TTM)
0.09
Profit Margin (>10% good)
0.10%
Operating Margin (TTM) (higher better)
0.07%
ROE (TTM) (>15% strong)
0.16%
EPS YoY (Quarterly) (>10% good)
-0.39
Revenue YoY (Quarterly) (>8% good)
0.16
Momentum
Bearish momentumValue
0.0612
Previous
0.0465
Trend
Rising
Signal Cross
No cross
As of
Sep. 12, 2025